{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T06:58:11Z","timestamp":1774681091279,"version":"3.50.1"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>To give an overview of recently published articles about the management of vasculo-Behcet's with particular emphasis on anticoagulation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Biologic agents are emerging as a potential therapeutic option in refractory vasculo-Behcet with a good safety profile. Evidence further shows that following nonpulmonary aneurysm repair, there is a reduced risk of recurrent aneurysmal formation at the operative site in patients treated with immunosuppressants in addition to their surgery, than those undergoing surgical intervention alone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Behcet disease patients are at risk of developing multiple vascular complications including thrombosis and aneurysms. Treatment should focus on reducing inflammation; and the role of anticoagulation is still debatable.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000458","type":"journal-article","created":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T19:55:41Z","timestamp":1508961341000},"page":"50-56","source":"Crossref","is-referenced-by-count":29,"title":["A review of current management of vasculo-Behcet's"],"prefix":"10.1097","volume":"30","author":[{"given":"Mira","family":"Merashli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rozana El","family":"Eid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imad","family":"Uthman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"e2011026","DOI":"10.4084\/mjhid.2011.026","article-title":"Beh\u00e7et's syndrome and thrombosis","volume":"3","author":"Seyahi","year":"2011","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R2-20230829","article-title":"Exploring the variability in Behcet's disease prevalence: a meta-analytical approach","author":"Maldini","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00005792-200301000-00006","article-title":"The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center","volume":"82","author":"Kural-Seyahi","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/BOR.0b013e3283410088","article-title":"Major vessel involvement in Behcet's disease: an update","volume":"23","author":"Calamia","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1053\/euhj.2000.2515","article-title":"Platelet activation: assessment and quantification","volume":"22","author":"Kamath","year":"2001","journal-title":"Eur Heart J"},{"key":"R6-20230829","doi-asserted-by":"crossref","DOI":"10.1007\/978-88-470-5477-6_11","article-title":"Cardiovascular issues: aneurysms and pseudoaneurysms, thrombosis, atherosclerosis, and cardiac involvement","author":"Silvestri","year":"2014","journal-title":"Beh\u00e7et's syndrome: from pathogenesis to treatment"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00296-006-0281-6","article-title":"Immunopathogenesis of Beh\u00e7et's disease with special emphasize on the possible role of antigen presenting cells","volume":"27","author":"Pay","year":"2007","journal-title":"Rheumatol Int"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaci.2011.05.029","article-title":"Critical role of IL-21 in modulating TH17 and regulatory T cells in Behcet disease","volume":"128","author":"Geri","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jbspin.2010.02.022","article-title":"A study on thrombophilic factors in Italian Behcet's patients","volume":"77","author":"Caramaschi","year":"2010","journal-title":"Joint Bone Spine"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaut.2015.10.002","article-title":"Epigenomic functional characterization of genetic susceptibility variants in systemic vasculitis","volume":"67","author":"Sawalha","year":"2016","journal-title":"J Autoimmun"},{"key":"R11-20230829","first-page":"71","article-title":"Behcet's disease as a model of venous thrombosis","volume":"4","author":"La Regina","year":"2010","journal-title":"Open Cardiovasc Med J"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.survophthal.2005.04.009","article-title":"Current concepts in the etiology and treatment of Behcet disease","volume":"50","author":"Evereklioglu","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/15569527.2011.554480","article-title":"Oxidative stress impairs endothelial nitric oxide levels in Behcets\u2019 disease","volume":"30","author":"Onur","year":"2011","journal-title":"Cutan Ocul Toxicol"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3109\/03009749509095184","article-title":"Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behcet's disease","volume":"24","author":"Ozoran","year":"1995","journal-title":"Scand J Rheumatol"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1055\/s-0038-1650405","article-title":"Circulating thrombomodulin as a clue of endothelial damage in Behcet's disease","volume":"75","author":"Haznedaroglu","year":"1996","journal-title":"Thromb Haemost"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1155\/MI.2005.237","article-title":"Serum levels of soluble P-selectin are increased and associated with disease activity in patients with Behcet's syndrome","volume":"2005","author":"Turkoz","year":"2005","journal-title":"Mediators Inflamm"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0049-0172(97)80010-8","article-title":"Specificity, pathogenecity, and clinical value of antiendothelial cell antibodies","volume":"27","author":"Belizna","year":"1997","journal-title":"Semin Arthritis Rheum"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S0046-8177(85)80250-1","article-title":"Pathologic features of Beh\u00e7et's syndrome: a review of Japanese autopsy registry data","volume":"16","author":"Lakhanpal","year":"1985","journal-title":"Hum Pathol"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/CIRCULATIONAHA.115.017738","article-title":"Neutrophil activation promotes fibrinogen oxidation and thrombus formation in Behcet disease","volume":"133","author":"Becatti","year":"2016","journal-title":"Circulation"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10067-007-0713-z","article-title":"Multiple peripheral arterial and aortic aneurysms in Behcet's syndrome: a case report","volume":"27","author":"Jayachandran","year":"2008","journal-title":"Clin Rheumatol"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1024\/0301-1526.32.3.149","article-title":"Surgical treatment of vasculo-Behcet's disease. A review of patients with concomitant multiple aneurysms and venous lesions","volume":"32","author":"Ceyran","year":"2003","journal-title":"Vasa"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"760484","DOI":"10.5402\/2012\/760484","article-title":"Behcet's disease: new concepts in cardiovascular involvements and future direction for treatment","volume":"2012","author":"Owlia","year":"2012","journal-title":"ISRN Pharmacol"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1510\/icvts.2010.260976","article-title":"Rapidly growing aortic arch aneurysm in Behcet's disease","volume":"12","author":"Kojima","year":"2011","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"(4 Suppl 45)","key":"R24-20230829","first-page":"S70","article-title":"Serum MMP-2 and MMP-9 in patients with Behcet's disease: do their higher levels correlate to vasculo-Behcet's disease associated with aneurysm formation?","volume":"25","author":"Pay","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/ard.2007.080432","article-title":"EULAR recommendations for the management of Behcet disease","volume":"67","author":"Hatemi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1161\/CIRCULATIONAHA.114.008828","article-title":"Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration","volume":"130","author":"Simes","year":"2014","journal-title":"Circulation"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1538574408315205","article-title":"Low-dose aspirin may prevent growth and later surgical repair of medium-sized abdominal aortic aneurysms","volume":"42","author":"Lindholt","year":"2008","journal-title":"Vasc Endovascul Surg"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s00330-008-0956-3","article-title":"Measurement and determinants of infrarenal aortic thrombus volume","volume":"18","author":"Golledge","year":"2008","journal-title":"Eur Radiol"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"55.e2","DOI":"10.1016\/j.jvs.2010.02.012","article-title":"An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance","volume":"52","author":"Thompson","year":"2010","journal-title":"J Vasc Surg"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"e494","DOI":"10.1097\/MD.0000000000000494","article-title":"Behcet disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses","volume":"94","author":"Alibaz-Oner","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1002\/art.34450","article-title":"Immunosuppressants reduce venous thrombosis relapse in Beh\u00e7et's disease","volume":"64","author":"Desbois","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10067-007-0685-z","article-title":"Treatment of venous thrombosis associated with Behcet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation","volume":"27","author":"Ahn","year":"2008","journal-title":"Clin Rheumatol"},{"key":"R33-20230829","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MD.0b013e3182428f49","article-title":"Spectrum of cardiac lesions in Behcet disease: a series of 52 patients and review of the literature","volume":"91","author":"Geri","year":"2012","journal-title":"Medicine (Baltimore)"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.surg.2015.11.022","article-title":"Outcomes of vascular intervention and use of perioperative medications for nonpulmonary aneurysms in Beh\u00e7et disease","volume":"159","author":"Liu","year":"2016","journal-title":"Surgery"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/2040622314523062","article-title":"Update on the therapy of Beh\u00e7et disease","volume":"5","author":"Saleh","year":"2014","journal-title":"Ther Adv Chronic Dis"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":"A controlled trial of azathioprine in Behcet's syndrome","volume":"322","author":"Yazici","year":"1990","journal-title":"N Engl J Med"},{"key":"R38-20230829","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9394(14)72840-5","article-title":"Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet's disease","volume":"118","author":"Whitcup","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"R39-20230829","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/bjo.76.4.241","article-title":"Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial","volume":"76","author":"Ozyazgan","year":"1992","journal-title":"Br J Ophthalmol"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","article-title":"Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease","volume":"1","author":"Masuda","year":"1989","journal-title":"Lancet"},{"issue":"(3 Suppl 4)","key":"R41-20230829","first-page":"136","article-title":"Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome","volume":"20","author":"BenEzra","year":"1988","journal-title":"Transplant Proc"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s10067-005-0070-8","article-title":"CNS involvement occurs more frequently in patients with Behcet's disease under cyclosporin A (CSA) than under other medications: results of a retrospective analysis of 117 cases","volume":"25","author":"Kotter","year":"2006","journal-title":"Clin Rheumatol"},{"key":"R43-20230829","first-page":"391","article-title":"Treatment of thrombophlebitis of Behcet's disease with low dose cyclosporin A","volume":"17","author":"Cantini","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"R44-20230829","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.berh.2016.08.002","article-title":"Beh\u00e7et's disease: How to diagnose and treat vascular involvement","volume":"30","author":"Seyahi","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R45-20230829","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1583\/09-2812.1","article-title":"Effectiveness and safety of endovascular aneurysm treatment in patients with vasculo-Behcet disease","volume":"16","author":"Kim","year":"2009","journal-title":"J Endovasc Ther"},{"key":"R46-20230829","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jvs.2005.05.057","article-title":"The surgical treatment of arterial aneurysms in Behcet disease: a report of 16 patients","volume":"42","author":"Kalko","year":"2005","journal-title":"J Vasc Surg"},{"key":"R47-20230829","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jvs.2005.03.019","article-title":"Long-term outcome after surgical treatment of arterial lesions in Behcet disease","volume":"42","author":"Hosaka","year":"2005","journal-title":"J Vasc Surg"},{"key":"R48-20230829","first-page":"2103","article-title":"Arterial lesions in Behcet's disease. A study in 25 patients","volume":"22","author":"Le Thi Huong","year":"1995","journal-title":"J Rheumatol"},{"key":"R49-20230829","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jtcvs.2004.08.038","article-title":"Bilateral pulmonary artery aneurysm in Behcet syndrome: report of two operative cases","volume":"129","author":"Aroussi","year":"2005","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R50-20230829","article-title":"Outcomes of patients with Behcet's syndrome after pulmonary endarterectomy","author":"Yildizeli","year":"2017","journal-title":"Thorac Cardiovasc Surg"},{"key":"R51-20230829","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.bor.0000197995.27579.9b","article-title":"New approaches in the treatment of Adamantiades-Beh\u00e7et's disease","volume":"18","author":"Pipitone","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"R52-20230829","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.semarthrit.2011.02.006","article-title":"Resolution of Beh\u00e7et's syndrome associated pulmonary arterial aneurysms with infliximab","volume":"41","author":"Schreiber","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"R53-20230829","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/rheumatology\/kem103","article-title":"Infliximab in the treatment of hepatic vein thrombosis (Budd-Chiari syndrome) in three patients with Beh\u00e7et's syndrome","volume":"46","author":"Seyahi","year":"2007","journal-title":"Rheumatology"},{"key":"R54-20230829","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/acr.21557","article-title":"Behcet's disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis","volume":"64","author":"Adler","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R55-20230829","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10067-009-1272-2","article-title":"Adalimumab treatment for life threatening pulmonary artery aneurysm in Beh\u00e7et disease: a case report","volume":"29","author":"Lee","year":"2009","journal-title":"Clin Rheumatol"},{"key":"R56-20230829","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/1756-185X.12732","article-title":"Safety profile of biologic agents for Beh\u00e7et's disease in a multicenter observational cohort study","volume":"20","author":"Cantarini","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"R57-20230829","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","article-title":"Anakinra treatment in drug-resistant Behcet's disease: a case series","volume":"34","author":"Cantarini","year":"2015","journal-title":"Clin Rheumatol"},{"key":"R58-20230829","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/RHU.0b013e318284735c","article-title":"Remission induction in a case of refractory Beh\u00e7et disease with alemtuzumab","volume":"19","author":"Perez-Pampin","year":"2013","journal-title":"J Clin Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201801000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T07:01:36Z","timestamp":1693292496000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201801000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000458","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}